India-market vardenafil search results frequently feature Vilitra, Zhewitra and Valif. These are names used in foreign-market product listings, not an FDA-approved U.S. generic directory. Reliable comparison begins with the named ingredient and formulation of each particular product, rather than assuming that a trade name proves authenticity, bioequivalence or lawful U.S. availability.
The available evidence is uneven. Centurion Laboratories presents numerous Vilitra-branded listings but some fields in its catalog conflict. Sunrise Remedies publishes Zhewitra single-agent and separately named vardenafil–dapoxetine combinations, and even its broad Zhewitra page contains an inconsistent dosage-form field. Indian pharmacy records describe Valif 20 tablets containing vardenafil, commonly attributed to Ajanta Pharma, although the exact company role and any additional presentations should not be inferred without independent primary documentation.
This directory is an orientation tool with evidence levels, not a ranking or an invitation to import prescription medicines. The ingredient’s U.S. regulatory pathway is explained at FDA-approved generic vardenafil; the individual Vilitra, Zhewitra and Valif pages handle brand-specific product identity.
A company-linked product catalog supports that the company publicly advertises a named product. A reputable market-specific medicine record can substantiate a listed composition, but neither alone establishes the identity of every pack found through exporters. A complete verified product record ideally includes full trade name, ingredient, strength, dosage form, national-market context and the company’s explicit role.
For this directory, “company-listed” means that the named supplier markets a product description; “retailer-recorded” means that an independent pharmacy catalog reports it; and “unverified for this variant” means available descriptions are inconsistent or incomplete. No evidence tier should be confused with U.S. FDA approval.
| Brand or variant | What available documentation reports | Evidence limitation |
|---|---|---|
| Vilitra / Centurion | Vardenafil tablets with multiple advertised strengths | Some named-SKU and strength fields conflict |
| Zhewitra / Sunrise | Vardenafil single-ingredient product family | Main catalog inconsistently labels form |
| Zhewitra Oral Jelly | Distinct Sunrise-listed vardenafil jelly | Not an FDA-approved U.S. ODT |
| Super Zhewitra | Vardenafil plus dapoxetine | Combination, not plain vardenafil |
| Valif 20 | Retail medicine records list vardenafil 20 mg | Confirm maker role and original pack |
| U.S. generic vardenafil | FDA applications for named products | Not an endorsement of these foreign brands |
Centurion Laboratories publishes a Vilitra-oriented vardenafil table including conventional tablet names and higher-strength marketing entries. A notable data-quality problem is that some product headings, brand fields and strength fields disagree; one entry headed as a different strength contains another number in the detail row.
That inconsistency matters because a copied seller description can easily turn a questionable field into a false dosage claim. Product-specific identity should be treated as provisional until the actual package or authenticated source is checked. The Vilitra page dissects those record conflicts.
Sunrise Remedies lists a Zhewitra vardenafil family and names Zhewitra Oral Jelly and Zhewitrasoft as additional formulations. The company also lists Super Zhewitra, which contains vardenafil and dapoxetine; a separate Extra Super name is also presented as a combination in its catalog narrative.
These are different product identities. Dapoxetine adds a second pharmacologic component and cannot be silently grouped with a one-ingredient vardenafil tablet. Nor does a jelly or soft formulation become equivalent to a U.S. 10 mg orally disintegrating tablet by virtue of dissolving differently. See the brand-specific evidence assessment.
Indian pharmacy catalogues report Valif 20 as an oral tablet containing vardenafil 20 mg and associate it with Ajanta Pharma. That supports a more focused identity claim than an open-ended export catalogue. It does not prove that every Valif-labelled medicine shares a single manufacturing site or that other strengths are currently produced.
This narrower scope is important for editorial accuracy. Rather than populate the table with speculative 10 mg, 40 mg or combination listings, the Valif page explains the 20 mg record and what remains unverified at a company-role or package level.
A labeled conventional vardenafil tablet is not the same dosage form as a flavored jelly, a soft tablet or the FDA-approved 10 mg ODT product. Oral-disintegrating technology, formulation and drug exposure are product-specific. U.S. generic ODT labels explicitly warn against interchangeability with 10 mg film-coated vardenafil.
Imported descriptions that use “oral,” “soft,” “professional,” or “jelly” need their own composition and regulatory evidence. A seller’s claim of faster action does not establish approved equivalence or a clinically demonstrated benefit. The ODT product guide covers the U.S. formulation distinction.
An India-market medicine can appear under a company’s marketing brand while finished-dose production, export or local distribution is performed by another entity. The phrasing “made by” should not be taken from an unrelated reseller without product-specific corroboration.
Where a company presents a product catalogue, it supports corporate association. When a pharmacy listing names a marketer, that does not independently establish who physically manufactured every batch. Editorially, explain precisely what the source says and preserve unanswered questions instead of silently promoting association to confirmed manufacturing.
FDA approval attaches to specific products, applications and labeling. A medicine promoted as a generic in India is not thereby an FDA-approved therapeutic equivalent in the United States. Foreign trade names and price offers provide no substitute for checking the approved U.S. application.
Personal importation of unapproved prescription products is generally restricted, with narrow regulatory discretion that should not be treated as an ordinary purchasing route. U.S. patients should use legitimate assessment and licensed-pharmacy dispensing of an appropriate approved product. The U.S. buying guide covers that route.
Authentic vardenafil has known nitrate and riociguat contraindications, QT-related precautions and interactions involving CYP3A4 inhibitors and alpha-blockers. An uncertain foreign product adds questions about true ingredient identity, strength, quality and combination components.
Products that add dapoxetine must not be discussed as though they contain vardenafil alone. People should not adjust doses, combine PDE5 drugs or rely on seller directions in place of professional assessment. The ingredient interaction guide provides the U.S. clinical framework.
For any listed product, record the exact suffix, dosage form, labeled active ingredients and quantity of each, the corporate attribution and whether those data come from a primary producer or a third-party seller. Verify that the strength is internally consistent across the package and product record.
For U.S. use, add the separate questions: Is this precise drug FDA approved? Is the dispensing pharmacy licensed? Is there a valid prescription? A brand name alone cannot answer any of those questions.
Their India-market names or ingredient claims do not establish approval. Check FDA approval for the exact U.S. product application.
No. Public Centurion listings show several named products and some inconsistent fields, requiring product-by-product verification.
No. Sunrise lists Super Zhewitra as a combination of vardenafil and dapoxetine.
No. A foreign-market jelly is not interchangeable with a separately approved U.S. orally disintegrating tablet.
India-market pharmacy records list a 20 mg vardenafil tablet and connect it with Ajanta Pharma; manufacturing details need package-level confirmation.
No. A brand-level catalogue does not authenticate a seller, lot or individual package.
Do not assume a lawful routine import pathway. Appropriate U.S.-approved products should be considered through licensed prescription channels.
Documented ingredients, dosage form, exact product identity, regulatory status and professional review matter more than a marketing name.